Dystrophin News and Research

RSS
Dystrophin is a rod-shaped cytoplasmic protein, and a vital part of a protein complex that connects the cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the cell membrane.
Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Acceleron Pharma and Shire announce joint development of ACE-031 for DMD

Research on iPS cells can imply potential cell therapy for X-linked disorders

Research on iPS cells can imply potential cell therapy for X-linked disorders

International study to improve treatments for Duchenne muscular dystrophy

International study to improve treatments for Duchenne muscular dystrophy

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

FDA grants Acceleron's ACE-031 orphan designation for treatment of DMD

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Columbus hospital receives PPMD grant to conduct clinical testing for Duchenne

Columbus hospital receives PPMD grant to conduct clinical testing for Duchenne

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy

BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy

Prosensa, GSK initiate additional programs for DMD

Prosensa, GSK initiate additional programs for DMD

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

Acceleron Pharma commences Phase 2 clinical trial of ACE-031 protein therapeutic in DMD patients

New therapeutic approach for Duchenne muscular dystrophy

New therapeutic approach for Duchenne muscular dystrophy

Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow

Muscular dystrophy: $1M grant for study of erectile dysfunction drugs in improving muscle blood flow

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

Cardiologist receives grant to study impact of erectile dysfunction drugs on muscular dystrophy patients

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

BioMarin Pharmaceutical reports GAAP net income of $4.7M for fourth-quarter 2009

BioMarin Pharmaceutical reports GAAP net income of $4.7M for fourth-quarter 2009

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

Link between dystrophin gene and age of cardiac disease onset in BMD patients identified

Link between dystrophin gene and age of cardiac disease onset in BMD patients identified

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD